Entering text into the input field will update the search result below

Context stock soars ~70% as trial partner Stemline's breast cancer drug gets FDA approval

Jan. 31, 2023 8:53 AM ETContext Therapeutics Inc. (CNTX) StockGHBy: Ravikash Bakolia, SA News Editor2 Comments

Pink ribbon and stethoscope on pink background. Breast cancer awareness concept

suravikin/iStock via Getty Images

Context Therapeutics (NASDAQ:CNTX) said its clinical trial collaborator Stemline Therapeutics' medicine Orserdu was approved by the U.S. Food and Drug Administration (FDA) to treat a type of breast cancer.

Menarini Group's unit Stemline's drug Orserdu (elacestrant) was approved by

Recommended For You

About CNTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CNTX--
Context Therapeutics Inc.